NCT06330441Recruiting
Pancreatic Cancer Screening in a Population at High Risk
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
Pancreatic cancer is one of the diseases with the worst prognosis, which is mainly due to the initial asymptomatic prognosis. Unfortunately, the incidence of this disease in the Czech Republic is still increasing. In a certain proportion of patients, it is possible to predict the disease, e.g. due to family burdens. Regular follow-up of such individuals is the subject of the SCREPAN study: "Pancreatic Cancer Screening in High-Risk Persons".
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 700 (estimated)
- First submitted
- 31 Dec 2023
- Start date
- 7 Jan 2022
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- Masaryk Memorial Cancer Institute
- Diseases
- Pancreatic cancer
- NCT number
- NCT06330441
What you commit to
- Study type: Interventional
- Planned participants: 700
- From 7 Jan 2022 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Inability to undergo radical curative surgery for a pancreatic tumor.
Other illness
- Incurable malignant cancer.
Other
- Inability to undergo scheduled imaging examinations.
Who the study is looking for
- willing to participate in the study
- age 18+
- arms specific criteria:
- A:
- chronic pancreatic disease in the context of cystic fibrosis or chronic pancreatitis
- age 50+
- B1:
- confirmed Peutz-Jegherson syndrome (mutSTK11) + age over 35 years or 10 years earlier than pancreatic ductal adenocarcinoma was diagnosed in the youngest family member
- familial melanoma syndrome (mutCDKN2A) + age over 40 years or 10 years before pancreatic ductal adenocarcinoma was diagnosed in the youngest family member
- confirmed hereditary pancreatitis (mutPRSS1) + age over 40 years or 20 years after the first attack
- B2:
- confirmed diagnosis of hereditary syndrome (Lynch syndrome /mutMLH1, mutMSH2, mutMSH6, mutPMS2, mutEPCAM/, HBOC /mutBRCA1, mutBRCA2, mutPALB2, mutATM/, familial adenomatous polyposis /mutAPC/, Li-Fraumeni syndrome /mutTP53/)
- at least one relative with a diagnosis of pancreatic ductal adenocarcinoma in family anamnesis at the same time (Grade I or II relative)
- age over 50 years, or 10 years before the pancreatic ductal adenocarcinoma was diagnosed in the youngest relative - which comes first
- C:
- positive family anamnesis of pancreatic ductal adenocarcinoma without hereditary syndrome context
- age 50+ or 10 years earlier than the youngest relative with pancreatic ductal adenocarcinoma - screening is recommended for all first-degree relatives of affected family members
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Masaryk Memorial Cancer Institute Coordinator of this site? Confirm its status | Brno | Czechia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.